First-line lorlatinib for advanced ALK-positive non-small-cell lung cancer

克里唑蒂尼 医学 间变性淋巴瘤激酶 肺癌 阿列克替尼 癌症研究 碱性抑制剂 肿瘤科 内科学 恶性胸腔积液
作者
W. Marston Linehan,Justin F. Gainor
出处
期刊:The Lancet Respiratory Medicine [Elsevier BV]
卷期号:11 (4): 302-304
标识
DOI:10.1016/s2213-2600(22)00488-x
摘要

The treatment framework for advanced non-small-cell lung cancer harbouring anaplastic lymphoma kinase (ALK) fusions has changed substantially since the discovery of crizotinib, a first-generation ALK tyrosine-kinase inhibitor (TKI). Three generations of ALK TKIs have since been developed, with increasing potency, CNS penetrance, and ability to overcome ALK-resistance mutations with each successive generation. 1 Cooper AJ Sequist LV Lin JJ Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management. Nat Rev Clin Oncol. 2022; 19: 499-514 Crossref PubMed Scopus (48) Google Scholar Multiple phase 3 trials have shown superior efficacy of second-generation ALK TKIs (alectinib, brigatinib, and ensartinib) compared with crizotinib, establishing next-generation ALK TKIs as preferred initial therapy. 1 Cooper AJ Sequist LV Lin JJ Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management. Nat Rev Clin Oncol. 2022; 19: 499-514 Crossref PubMed Scopus (48) Google Scholar More recently, interim analysis of the phase 3 trial CROWN showed favourable efficacy of first-line lorlatinib, a third-generation ALK TKI, compared with crizotinib. 2 Shaw AT Bauer TM de Marinis F et al. First-Line lorlatinib or crizotinib in advanced ALK-positive lung cancer. N Engl J Med. 2020; 383: 2018-2029 Crossref PubMed Scopus (419) Google Scholar With this rich therapeutic landscape, clinicians now face the key question of which next-generation ALK TKI to select. Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN studyThese updated, long-term data from CROWN show the durable benefit of lorlatinib over crizotinib in patients with treatment-naive, ALK-positive non-small-cell lung cancer and support the use of first-line lorlatinib in patients with and without baseline brain metastases. Full-Text PDF
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
陈少华完成签到 ,获得积分10
刚刚
下一秒发布了新的文献求助10
1秒前
杨乃彬完成签到,获得积分10
1秒前
取名叫做利完成签到,获得积分10
2秒前
赘婿应助喻义梅采纳,获得10
3秒前
小二郎应助小门采纳,获得10
4秒前
ll发布了新的文献求助10
7秒前
正直的鸿完成签到,获得积分10
12秒前
13秒前
万能图书馆应助高贵梦露采纳,获得10
14秒前
momo发布了新的文献求助10
16秒前
传奇3应助boltos采纳,获得10
17秒前
17秒前
18秒前
要减肥笑阳完成签到 ,获得积分10
19秒前
全若之发布了新的文献求助10
24秒前
Jasper应助momo采纳,获得10
26秒前
Kasom完成签到 ,获得积分10
33秒前
顺利一德完成签到,获得积分20
34秒前
香蕉觅云应助Afaq采纳,获得10
34秒前
34秒前
34秒前
manman完成签到,获得积分10
35秒前
35秒前
哈哈哈完成签到,获得积分10
35秒前
YamDaamCaa应助科研通管家采纳,获得30
36秒前
36秒前
领导范儿应助科研通管家采纳,获得10
36秒前
香蕉觅云应助科研通管家采纳,获得10
36秒前
36秒前
大个应助科研通管家采纳,获得10
36秒前
czh应助科研通管家采纳,获得20
36秒前
科研通AI2S应助科研通管家采纳,获得10
36秒前
酷波er应助科研通管家采纳,获得10
36秒前
纯情的天奇完成签到 ,获得积分10
38秒前
顺利一德发布了新的文献求助10
39秒前
潇湘雪月发布了新的文献求助10
39秒前
39秒前
胡萝卜发布了新的文献求助10
40秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989263
求助须知:如何正确求助?哪些是违规求助? 3531418
关于积分的说明 11253814
捐赠科研通 3270066
什么是DOI,文献DOI怎么找? 1804884
邀请新用户注册赠送积分活动 882084
科研通“疑难数据库(出版商)”最低求助积分说明 809136